Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewSalmeterol xinafoate
Description: Long-acting β2 agonist; bronchodilator
Chemical Name: 4-Hydroxy-α1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol 1-hydroxy-2-naphthalenecarboxylic acid salt
Purity: ≥99% (HPLC)
Biological Activity for Salmeterol xinafoate
Salmeterol xinafoate is a long-acting β2 adrenergic receptor agonist. Inhibits the release of histamine, leukotrienes and prostaglandin D2, and blocks GM-CSF production from human cultured mast cells. Exhibits efficacious bronchodilatory activity in patients with asthma or chronic obstructive pulmonary disease (COPD).
Compound Libraries for Salmeterol xinafoate
Salmeterol xinafoate is also offered as part of the Tocriscreen 2.0 Max and Tocriscreen FDA-Approved Drugs. Find out more about compound libraries available from Tocris.
Technical Data for Salmeterol xinafoate
| M. Wt | 603.75 |
| Formula | C25H37NO4.C11H8O3 |
| Storage | Desiccate at RT |
| Purity | ≥99% (HPLC) |
| CAS Number | 94749-08-3 |
| PubChem ID | 56801 |
| InChI Key | XTZNCVSCVHTPAI-UHFFFAOYSA-N |
| Smiles | OC(C2=CC(CO)=C(O)C=C2)CNCCCCCCOCCCCC1=CC=CC=C1.OC4=C(C(O)=O)C=CC3=CC=CC=C34 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for Salmeterol xinafoate
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 60.37 | 100 | |
| ethanol | 12.07 | 20 |
Preparing Stock Solutions for Salmeterol xinafoate
The following data is based on the product molecular weight 603.75. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.66 mL | 8.28 mL | 16.56 mL |
| 5 mM | 0.33 mL | 1.66 mL | 3.31 mL |
| 10 mM | 0.17 mL | 0.83 mL | 1.66 mL |
| 50 mM | 0.03 mL | 0.17 mL | 0.33 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
Product Datasheets for Salmeterol xinafoate
References for Salmeterol xinafoate
References are publications that support the biological activity of the product.
Akabane et al (2006) Effects of salme. xinafoate and flutic. propionate on immunological activation of human cultured mast cells. Allergol.Int. 55 387 PMID: 17130681
Rennard et al (2001) Use of a long-acting inhaled beta2-adrenergic agonist, salme. xinafoate, in patients with chronic obstructive pulmonary disease. Am.J.Respir.Crit.Care Med. 163 1087 PMID: 11316640
Roberts et al (1999) The long-acting beta2-agonist salme. xinafoate: effects on airway inflammation in asthma. Eur.Respir.J. 14 275 PMID: 10515401
If you know of a relevant reference for Salmeterol xinafoate, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Salmeterol xinafoate, Salmeterol xinafoate supplier, long, acting, beta2, b2, β2, adrenergics, adrenoceptors, agonists, LABAs, asthma, COPD, respiratory, disease, bronchodilators, Adrenergic, Beta-2, Receptors, 4712, Tocris Bioscience
8 Citations for Salmeterol xinafoate
Citations are publications that use Tocris products. Selected citations for Salmeterol xinafoate include:
Zaytseva et al (2013) Resonant waveguide grating biosensor-enabled label-free and fluorescence detection of cell adhesion. Sens Actuators B Chem 188 PMID: 24319319
C et al (2007) Effect of indacaterol, a novel long-acting beta2-agonist, on isolated human bronchi. Eur Respir J 29 575-81 PMID: 17135231
Rankovic et al (2011) Modulation of calcium-dependent inactivation of L-type Ca2+ channels via β-adrenergic signaling in thalamocortical relay neurons. PLoS One 6 e27474 PMID: 22164209
Sykes and Charlton (2012) Slow receptor dissociation is not a key factor in the duration of action of inhaled long-acting β2-adrenoceptor agonists. Br J Pharmacol 165 2672 PMID: 21883146
Nackley et al (2007) Catechol-O-methyltransferase inhibition increases pain sensitivity through activation of both beta2- and beta3-adrenergic receptors. Pain 128 199 PMID: 17084978
Scola et al (2009) The long-acting beta-adrenoceptor agonist, indacaterol, inhibits IgE-dependent responses of human lung mast cells. Br J Pharmacol 158 267 PMID: 19371332
Israël-Assayag et al (2015) ASM-024, a piperazinium compound, promotes the in vitro relaxation of β2-adrenoreceptor desensitized tracheas. Nat Commun 10 e0120095 PMID: 25799096
Pon et al (2016) The β2-adrenoceptor activates a positive cAMP-calcium feedforward loop to drive breast cancer cell invasion. FASEB J 30 1144 PMID: 26578688
Do you know of a great paper that uses Salmeterol xinafoate from Tocris? Please let us know.
Reviews for Salmeterol xinafoate
There are currently no reviews for this product. Be the first to review Salmeterol xinafoate and earn rewards!
Have you used Salmeterol xinafoate?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.